Everything in this article is accurate, regardless
Post# of 154339
(Total Views: 335)
Posted On: 10/25/2019 9:41:53 AM
Quote:
Everything in this article is accurate, regardless of their slant.
Not quite.
Quote:
CytoDyn's lead therapy is PRO 140 in treatment of HIV, which it claims to have blockbuster potential.
Yes, Cytodyn does claim that, because it's true. Has this author never taken at look at the clinical results?
Quote:
Instead of focusing all its efforts in a balls to the wall effort to secure FDA approval and then commercialize PRO 140, it's pursuing a variety of other indications for PRO 140.
The only non-HIV indication it's actively pursuing is mTNBC and great results from that alone can turn around the stock price.
ps. Either he reads ihub or posts there.
Quote:
CytoDyn has $0 revenue (p.27) and growing expenses (p. 4): Until it can start generating significant revenues from somewhere, it is entirely dependent on its ability to raise capital in order to continue its operations. Per its Q3 2019 10-Q (p. 27), CytoDyn expects no product revenue until the FDA approval of PRO 140.
When oh when will Cytodyn ever generate revenue. Does he think we're in Phase I?
Quote:
it is ill prepared for traversing the danger zone between FDA approval of PRO 140 and market acceptance of its new product.
Of course the market will ignore the only HIV drug that doesn't develop resistance.
Quote:
I am/we are long CYDY,
"I thought the company sucked in my last article and I bought it and still think it sucks, now sell me your shares cheap."
(2)
(0)